Treace Medical Concepts Logo
US89455T1097
A3CM04
TMCI

Treace Medical Concepts

Cargando cotizaciones...

Previsión

El precio objetivo medio de los analistas es de 5,92 € (-74,13 %). La mediana es de 5,92 € (-74,13 %).

Comprar
  3
Mantener
  5
Vender
  1

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • Treace Medical beats Q2 forecasts; shares jump about 24% premarket

    Treace Medical reported Q2 revenue of $45.4 million and an adjusted loss of $0.24 per share, with both revenue and EPS beating consensus estimates. The company cut operating expenses by 8% and reduced cash burn since the start of the year by 57%, lowering the net loss to $15.9 million. Treace slightly raised its full-year revenue guidance to $204–212 million and narrowed the adjusted EBITDA loss to $3–5 million, citing accelerated case volume and several product launches as drivers. The stock rose about 24% in premarket trading in response to the stronger results and the improved outlook. » Más en de.investing.com


  • Treace Medical Concepts reports Q4 2025 revenue decline, stock rises slightly

    Treace Medical Concepts reported Q4 2025 revenue of $62.5 million, a 9% decline year‑over‑year, and a loss per share of $0.16, missing expectations. Gross margin remained stable at 80.6%, while operating expenses rose slightly to $56.3 million. The company attributed the revenue decline to a shift in the product mix toward lower‑priced offerings. The stock gained 0.48% in premarket trading, and Treace plans several product launches in 2026 (including Lapiplasty Lightning and IntelliGuide PSI) to support growth. » Más en de.investing.com


  • Treace Medical adjusts strategy: product expansion and cost cuts to counter falling demand

    Treace Medical reports annual revenue of over $200 million but sees weaker demand for the Lapoplasty system. The company is expanding its portfolio for bunion treatments, introducing new lower-priced products, and stepping up surgeon training as well as AI-powered diagnostics with IntelliGuide. Financial measures include stable gross margins in the high-70% range and a 45% reduction in cash burn; further decisions are expected after the Q4 numbers. » Más en de.investing.com


  • Treace Medical raises Q3 revenue 11% to $50.2m but remains loss-making

    Treace Medical reported Q3 2025 revenue up 11% to $50.2m, above analysts’ estimate of $49.66m. The company recorded a net loss of $16.3m, or $0.26 per share; gross margin fell to 79.1%. Adjusted EBITDA loss improved 49% to $2.6m. For 2025 Treace expects revenue of $211–213m and an adjusted EBITDA loss of $6.5–7.5m; management emphasizes a focus on profitability and market expansion. » Más en de.investing.com


  • Treace Medical Concepts beats Q2 forecasts and shares rise after hours

    Treace Medical Concepts Inc. reported a Q2 2025 loss per share of $0.28 versus $0.29 expected and revenue of $47.4 million, topping estimates. Net loss and adjusted EBITDA improved significantly; the stock rose 3.84% after hours. For 2025, the company guides to $224–$230 million in revenue and breakeven on adjusted EBITDA, supported by new product launches and market expansion. » Más en de.investing.com

Datos financieros de la empresa

En el último trimestre, Treace Medical Concepts tuvo unos ingresos de 42,6 M € y un beneficio neto de -11,09 M €
(EUR) septiembre de 2026
YoY
Ingresos 42,6 M 0,44 %
Beneficio bruto 33,86 M 0,07 %
Beneficio neto -11,09 M 20,07 %
EBITDA -9,7 M 6,52 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
264,93 M €
Número de acciones
65,56 M
Máximo/mínimo de 52 semanas
4,95 € - 1,06 €
Dividendos No
Beta
1,56
Ratio P/E
-5,16
Ratio PEG
0,49
Ratio P/B
4,72
Ratio P/S
1,43

Perfil de la empresa

Treace Medical Concepts, Inc., una empresa de dispositivos médicos ortopédicos, se dedica al diseño, la fabricación y la comercialización de dispositivos médicos para cirujanos de pie y tobillo en los Estados Unidos. Ofrece el procedimiento Lapiplasty, que permite a los cirujanos podólogos tratar las tres dimensiones del juanete, proporcionando a los pacientes una mejora estética y médica. La empresa también ofrece el sistema de precisión Lapiplasty Mini-Incision. Además, ofrece productos para procedimientos quirúrgicos auxiliares, incluidas las osteotomías de Akin, las osteotomías de Weil, la estabilización intercuneiforme, las artrodesis de la articulación tarsometatarsiana lateral y la obtención de injertos óseos autólogos, así como para la artrodesis MTP. Treace Medical Concepts, Inc. fue fundada en 2013 y tiene su sede en Ponte Vedra Beach, Florida.

Nombre
Treace Medical Concepts
CEO
John T. Treace
Sede Ponte Vedra, fl
Estados Unidos
Sitio web
Sector
Consumo discrecional
Industria
Bienes duraderos del hogar
Salida a bolsa
23/04/2021
Empleados 450

Símbolos bursátiles

Bolsa Símbolo
NASDAQ
TMCI
🍪

Parqet  usa cookies. Más información